title: Effect of ofloxacin on theophylline pharmacokinetics at clinical dosage in dogs.
abstract: We examined the effects of ofloxacin (OFX) and norfloxacin (NFX) on theophylline (TP) pharmacokinetics in dogs. OFX, as a noncompetitive and mechanism-based inhibitor, and NFX, as a noncompetitive inhibitor, were orally administered (5 mg/kg) for a single dose or multiple doses (12 hourly for 3 days). TP (5 mg/kg, i.v) was injected at 2 h after the final dose of the fluoroquinolones (FQs). The same dose of TP was injected (i.v) 3 weeks before the start of FQs treatment for control. Multiple doses of OFX significantly reduced the total body clearance (Cl(B)) of TP from 0.117 to 0.085 L/h/kg, although a single dose did not change it. Neither a single dose nor multiple doses of NFX changed the TP pharmacokinetics. Plasma NFX concentrations increased after multiple doses. Those of OFX also increased but were still two orders of magnitude below the K(i) for noncompetitive inhibition of CYP1A in dogs. Time-dependent reduction in Cl(B) of TP suggests that mechanism-based inhibition of OFX was the major mode to decrease Cl(B) of TP. The mechanism-based inhibition may result in substantial inhibition of CYP1A activities in clinical conditions.
authors.affiliation: Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Tokyo, Japan.
authors.forename: N L
authors.initials: NL
authors.lastname: Regmi
authors.forename: A M
authors.initials: AM
authors.lastname: Abd El-Aty
authors.forename: R
authors.initials: R
authors.lastname: Kubota
authors.forename: A
authors.initials: A
authors.lastname: Tomita
authors.forename: M
authors.initials: M
authors.lastname: Shimoda
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019540:Area Under Curve; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D007275:Injections, Intravenous; D008657:Metabolic Clearance Rate; D009643:Norfloxacin / Q000494:pharmacology*; D015242:Ofloxacin / Q000494:pharmacology*; D011485:Protein Binding; D013806:Theophylline / Q000378:metabolism / Q000493:pharmacokinetics*; D014665:Vasodilator Agents / Q000378:metabolism / Q000493:pharmacokinetics*
chemical_list: D000900:Anti-Bacterial Agents; D014665:Vasodilator Agents; D015242:Ofloxacin; D013806:Theophylline; D009643:Norfloxacin